Clearing Amyloid Provides Alzheimer’s Benefit, But With Risks That Need Careful Management
Sponsors Plan Extensive Education About Safety
Executive Summary
Eisai/Biogen’s lecanemab showed that reducing amyloid can slow Alzheimer’s disease progression, but prescribers will have to weigh the potential benefit versus safety risks on a patient-by-patient basis.
You may also be interested in...
CTAD 2023: Medical Centers Adapt To Leqembi Testing, Monitoring Requirements
Neurologists shared their health care facilities’ protocols as they begin treating Alzheimer’s patients with the first anti-amyloid treatment to win both US FDA approval and Medicare coverage – Eisai/Biogen’s Leqembi.
Is Lecanemab Plus t-PA A Deadly Combination? One Case Study May Shed Light
A letter in the New England Journal of Medicine suggests the death of one extension trial participant treated with t-PA may have been caused by lecanemab, but a response notes fatal intracerebral hemorrhages have been seen after t-PA in certain patients in the absence of anti-amyloid drugs.
Is Lecanemab Plus t-PA A Deadly Combination? One Case Study May Shed Light
A letter in the New England Journal of Medicine suggests the death of one extension trial participant treated with t-PA may have been caused by lecanemab, but a response notes fatal intracerebral hemorrhages have been seen after t-PA in certain patients in the absence of anti-amyloid drugs.